Drug design

DeepCure Turns Complex Drug Designs into Testable Molecules with Robotic Synthesis Breakthrough

Retrieved on: 
tisdag, maj 28, 2024
Hardware, Health Technology, Data Management, Other Health, Technology, Pharmaceutical, Apps, Applications, General Health, Medical Devices, Artificial Intelligence, Biotechnology, Science, Software, Other Science, Research, Health, Automation, Nirmatrelvir, Patent, Inspiration, DMTA, Invention, AI, Nirmatrelvir/ritonavir, Drug discovery, Synovial joint, Therapy, OLED, Drug design, Fine chemical

DeepCure, a leader in discovering novel therapeutics powered by AI and automation, announced today that its Inspired Chemistry™ platform had achieved a breakthrough in chemical synthesis.

Key Points: 
  • DeepCure, a leader in discovering novel therapeutics powered by AI and automation, announced today that its Inspired Chemistry™ platform had achieved a breakthrough in chemical synthesis.
  • The Inspired Chemistry™ platform, which is available to early access partners, is expected to drive further innovation in drug discovery by enabling researchers to rapidly synthesize and test more diverse and complex molecule designs.
  • Small molecule drug discovery still depends on molecules that are handmade by chemists.
  • However, the high cost and long timelines of manual synthesis limit the number of molecules that drug discovery researchers can purchase and test.

Exscientia Business Update for First Quarter 2024

Retrieved on: 
tisdag, maj 21, 2024
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Research, Software, Artificial Intelligence, Science, Clinical Trials, Partnership, CTA, Bristol Myers Squibb, Patient, Intelligence, Automation, Lymphoid leukemia, BST, Investment, Calendar, IND, PKC, Federal Reserve Bank, EDT, Fruit, Merck Group, CDK7, Engineering, CLL, AI, AML, Drug discovery, Medicine, International, ID, Inflammation, G&A, LSD1, MALT1, Drug design, Pharmaceutical industry

Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below.
  • Exscientia will host a conference call Tuesday, May 21 at 1:30 p.m. BST / 8:30 a.m. EDT.
  • Revenue: Revenue for the first quarter of 2024 was $6.7 million, compared to $7.3 million for the three months ended March 31, 2023.
  • Cash inflows: For the three months ended March 31, 2024, Exscientia received $4.5 million in cash inflows from its collaborations as compared to $0.5 million during the first quarter 2023.

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design

Retrieved on: 
tisdag, maj 14, 2024
Biotechnology, Health, Pharmaceutical, Technology, Artificial Intelligence, Doctor of Philosophy, Protein, Translation, Cytokine, Drug development, G protein-coupled receptor, Language, Eurosport 1, Harvard University, Senior, AI, Khosla Ventures, Medicine, Therapy, Nabla, AstraZeneca, Nature Methods, Multimedia, Antibody, Synthetic media, Drug design

View the full release here: https://www.businesswire.com/news/home/20240514763517/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240514763517/en/
    Nabla Bio Co-Founders Surge Biswas and Frances Anastassacos at the company's labs in Cambridge, Mass.
  • Nabla’s generative protein design platform is unlocking hundreds of these previously inaccessible targets by enabling the precise design of conformation- and target-selective antibody binders.
  • Across its collaborations, Nabla has demonstrated the broad applicability of its platform, beyond drug design for multipass membrane proteins.
  • These results are an important step in translating generative protein design to clinical therapies and evidence of Nabla’s expanding capabilities.

Hewlett Packard Enterprise Delivers Second Exascale Supercomputer, Aurora, to U.S. Department of Energy’s Argonne National Laboratory

Retrieved on: 
måndag, maj 13, 2024
Technology, Professional Services, Public Policy, Government, Science, Data Analytics, Semiconductor, Carriers and Services, Other Science, Research, Government Technology, White House, Federal Government, Contracts, Networks, Defense, Hardware, Data Management, Artificial Intelligence, Partnership, Intel, HPE, Deep learning, MXP, GameChanger, Data center, Engineering, Brain mapping, AI, Physics, Neuron, Cray, Hewlett Packard Enterprise, Argonne National Laboratory, HPC, Drug design, GPU, Management

Today at ISC High Performance 2024, Hewlett Packard Enterprise (NYSE: HPE) announced that it has delivered the world’s second exascale supercomputer, Aurora, in collaboration with Intel for the United States Department of Energy’s Argonne National Laboratory.

Key Points: 
  • Today at ISC High Performance 2024, Hewlett Packard Enterprise (NYSE: HPE) announced that it has delivered the world’s second exascale supercomputer, Aurora, in collaboration with Intel for the United States Department of Energy’s Argonne National Laboratory.
  • Aurora is built with the HPE Cray EX supercomputer, which is purpose-built to support the magnitude and scale of exascale.
  • “Aurora is a first-of-its-kind supercomputer and we expect it to be a gamechanger for researchers,” said Rick Stevens, associate laboratory director and distinguished fellow at Argonne National Laboratory.
  • “Our ongoing collaboration with Argonne National Laboratory and HPE has resulted in promising early science success stories.

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Retrieved on: 
onsdag, maj 8, 2024
FDA, CFO, Research, CRC, Partnership, PDAC, ASCO, CD137, AACR, Biomarker, EGFR, Lung cancer, Non-small-cell lung cancer, Drug design, Illinois State University, HER2, Food, Bristol Myers Squibb, Patent, Eli Lilly and Company, BLA, NRG1, Therapy, NSCLC, PYC, Safety, Cetuximab, Pembrolizumab, Marketing, Clinical trial, CD3, MET, HNSCC, Gilead Sciences, Betta, Epitope, Biologics license application, Patient, Antigen, Head, Pharmaceutical industry

Merus plans to provide updated efficacy, durability and safety data of this cohort in the second half of 2024.

Key Points: 
  • Merus plans to provide updated efficacy, durability and safety data of this cohort in the second half of 2024.
  • In 2024, Merus is planning to initiate the evaluation of petosemtamab with standard chemotherapy in 2L CRC.
  • During the first quarter of 2024, Merus achieved a milestone of $1 million for candidate nomination and expects to receive payment in the second quarter of 2024.
  • In March 2024, Merus and Gilead Sciences announced a collaboration to discover novel antibody based trispecific T-cell engagers using Merus’ patented Triclonics® platform.

Dyno Therapeutics to Accelerate Design of High-Performance Biological Sequences Using NVIDIA AI

Retrieved on: 
torsdag, maj 9, 2024
Technology, Research, Genetics, Software, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Sequence, Brain, Drug design, Protein, AI, Dyno, Business development, RNA, AAV, Engineering, DNA, Patient, Eye, NVIDIA, Drug discovery, Therapy, Algorithm, Medical imaging

Dyno Therapeutics today announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design.

Key Points: 
  • Dyno Therapeutics today announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design.
  • Over the past decade, Dyno has pioneered an AI-powered approach to sequence design, creating some of the first in vivo-validated biologics using generative AI.
  • Dyno believes transformative sequence design capabilities can be brought within reach using its extensive proprietary datasets and the scale NVIDIA’s compute platform enables.
  • “NVIDIA’s collaboration with Dyno will optimize and scale high-performance biological sequence design, helping to dramatically accelerate the pace of drug discovery and development.”
    All patients can potentially benefit from the ability to design therapies based on biological sequences.

Avicenna Introduces Machine Learning-Enhanced Medicinal Chemistry Platform to Accelerate the Last Mile of Small Molecule Drug Discovery

Retrieved on: 
onsdag, maj 8, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, FDA, Drug design, Hearing, Kaiser, Risk, Ligand, Fasudil, Machine learning, Liotta, Partnership, Virology, ROCK, DRS, Engineering, Mathematics, Algorithm, Therapy, Microsoft, Chemistry, Neurology, DSM-IV codes, Medicine, Failure, Biology, Drug development, Emory University, Drug discovery, Chronic kidney disease, Microsoft Research, Cheminformatics, Pharmaceutical industry

Avicenna Biosciences today introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery.

Key Points: 
  • Avicenna Biosciences today introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery.
  • “Avicenna is applying novel ML methods to navigate the unknowns in medicinal chemistry and design around them.
  • Our methods allow a drug design team to learn from years of failure and optimize against validated targets more efficiently.
  • For more information on Avicenna and its technology platform or to inquire about partnership opportunities, visit www.avicenna-bio.com .

Vilya Announces New Publication in Science Validating Foundational Approach to Design of Novel Chemically Diverse Macrocycles

Retrieved on: 
torsdag, april 25, 2024
University, Cancer, Drug design, Protein, Biochemistry, Nature, HDAC, SARS-CoV-2, Research, Macrocycle, Medicine, BAK, HDAC6, MCL1, Drug discovery, IPD, Pharmaceutical industry

SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely targets disease biology, today announced the publication of a new study in Science that validates the company’s foundational drug discovery approach. The company’s platform, which is based on an exclusive license to the technology utilized in the study, leverages advanced computational approaches to design macrocycles with atomic-level accuracy that enable optimized drug-like properties.

Key Points: 
  • “Macrocycles are promising drug-like compounds, but incorporating diverse chemistries has historically been very difficult.
  • “Our platform, which leverages our proprietary computational design, rapidly generates both chemically and structurally diverse drug-like macrocyclic compounds.
  • They then synthesized a focused subset of 18 macrocycles and found the majority aligned closely to their predicted models, thereby validating the computational design approach.
  • “The publication in Science of the core capabilities of this technology, which we have licensed and integrated into our own proprietary platform, provides further validation of our approach.

Genscience and Deerfield Management Announce Nature Publication Reporting Positive Impact of Genetic Evidence to Aid Discovery of More Effective Drug Targets

Retrieved on: 
onsdag, april 17, 2024
Drug design, Probability, DOI, Broad Institute, Hematology, Health, Doctor of Philosophy, Disease, Human, Partner (business rank), EV, Optimism, Drug development, Drug discovery, Biotechnology, Gene, Pharmaceutical industry

NEW YORK, April 17, 2024 /PRNewswire/ -- Genscience LLC, a company applying genetic evidence and proprietary platforms for drug discovery and development and an affiliate of Deerfield Management Company ("Deerfield"), a healthcare investment firm, today announced a new study that shows incorporating genetic evidence into drug design significantly increases the probability of successful development by up to 2.6 times compared to when genetic evidence is absent. The new study appeared in the April 17, 2024 issue of the peer-reviewed journal Nature.¹ The study also documents new findings regarding how different characteristics of genetic evidence impact drug development success.

Key Points: 
  • The new study appeared in the April 17, 2024 issue of the peer-reviewed journal Nature .¹ The study also documents new findings regarding how different characteristics of genetic evidence impact drug development success.
  • "These findings further demonstrate that genetic evidence is the most effective means to improve drug discovery and development success rates and R&D efficiency," said Matt Nelson, PhD, Chief Executive Officer of Genscience and Vice President of Genetics and Genomics, Deerfield Discovery and Development (3DC).
  • "This new data helps illustrate the power of genetic evidence to enrich our understanding of the relationship between a potential drug target and the disease we seek to treat."
  • Increasing emphasis on drug mechanisms with supporting genetic evidence is expected to increase success rates and lower the cost of drug discovery and development.

Lexogen launches end-to-end solutions for FFPE Transcriptomics

Retrieved on: 
onsdag, april 10, 2024
Cancer, Drug design, Paraffin, Transcriptome, Small RNA, Tissue, Gene expression profiling, RNA, Research, Carcinogenesis, Illumina, Data analysis, Neoplasm, Biomarker, RNA-Seq, A-DNA, Vaccine

Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.

Key Points: 
  • Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.
  • Lexogen's FFPE Transcriptomics line includes the SPLIT One-Step FFPE RNA Extraction Kit, QuantSeq FFPE 3' mRNA-Seq Library Prep Kit for gene expression profiling, and CORALL FFPE Whole Transcriptome RNA-Seq with a seamlessly integrated gDNA removal step for whole transcriptome RNA-Seq.
  • The SPLIT One-Step FFPE RNA Extraction Kit allows easy and effective extraction of RNA from FFPE samples in less than 2 hours.
  • QuantSeq FFPE and CORALL FFPE are compatible with SPLIT One-Step FFPE RNA Extraction, include purification solutions and Unique Dual Indices, and come with complimentary data analysis on Lexogen's Kangooroo data analysis platform.